BACKGROUND: Psoriasis is a chronic relapsing inflammatory @entity272 . @entity14288 , @entity19597 ( @entity19597 ), @entity9086 , and high--sensitivity C--reactive protein (hs--CRP) are inflammatory biomarkers. However, with the exception of hs--CRP, the role of these markers in the pathogenesis of @entity1569 is yet to be elucidated. OBJECTIVE: This study investigated @entity14288 , @entity19597 , @entity9086 , and hs--CRP levels in the serum of psoriatic @entity1 and healthy controls. METHODS: A total of 56 @entity1 suffering from @entity1569 and 34 age--matched controls were included in the study. @entity14288 , @entity19597 , @entity9086 , and hs--CRP serum levels were evaluated by ELISA. The @entity1569 area severity index (PASI) was calculated in all psoriatic @entity1 and @entity1 were divided in two groups according to PASI <10 or >= 10. RESULTS: The serum concentration of soluble @entity14288 was significantly lower in psoriatic @entity1 compared to healthy controls (1.33  0.32 pg/mL, 1.72  0.39 pg/mL, respectively;; p<0.001). The serum concentrations of soluble @entity19597 and hs--CRP were significantly higher in psoriatic @entity1 compared to healthy controls ( @entity19597 : 2.05  0.46 pg/mL, 1.82  0.46 pg/mL, hs--CRP: 4.97  3.53 mg/L, 3.48  0.08 mg/L, respectively;; p<0.05). There was no significant difference in the serum concentration of soluble @entity9086 between psoriatic @entity1 and the control group (1.37  0.55 ng/mL, 1.54  0.79 ng/mL, respectively; p>0.05). The mean PASI score was 9.1  8.2 in the @entity1 group. A total of 36 @entity1 had PASI <10 and 20 @entity1 had PASI >= 10. The serum concentration of @entity14288 was the only marker to exhibit a significant difference between the low and high PASI groups (1.40  0.27 pg/mL and 1.20  0.37 pg/mL, respectively;; p<0.05). CONCLUSIONS: These findings suggest that @entity14288 and @entity19597 may play a role in the pathogenesis of @entity1569 and can be used as markers of the disease. Furthermore, @entity14288 levels may reflect the severity of disease.

Novel inflammatory markers in XXXX : @entity14288 , @entity19597 ( @entity19597 ), and @entity9086 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity14288 :: ('145264', 'Gene') :: ['Vaspin', 'vaspin'] @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis'] @entity9086 :: ('1116', 'Gene') :: ['YKL--40'] @entity272 :: ('MESH:D012871', 'Disease') :: ['skin disease'] @entity19597 :: ('8639', 'Gene') :: ['vascular adhesion protein--1', 'VAP--1']
@entity1569 :: (MESH:D011565,Disease) :: ['psoriasis vulgaris']
